Question 1

What is Humana's P/FCF ratio?

Accepted Answer

Humana (HUM) P/FCF ratio is 37.7× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month free cash flow, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/FCF ratio calculated?

Accepted Answer

P/FCF = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Free Cash Flow, where Free Cash Flow = Operating Cash Flow − Capital Expenditures. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/FCF ratio?

Accepted Answer

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.

Question 4

What is a good P/FCF ratio for Humana?

Accepted Answer

Mature companies that consistently convert profit into cash often trade at 15–25× P/FCF; capital-intensive businesses with lumpy capex typically trade lower. Compare against sector peers and against the company's own multi-year average — single-year P/FCF can be distorted by working-capital swings. For Humana specifically, the relevant sector benchmark is the current sector median of 19.1×.

Question 5

Is Humana's P/FCF ratio high or low?

Accepted Answer

Humana's P/FCF ratio of 37.7× is above its own 5-year average of 29.2× and above the sector median of 19.1×. That places the current reading at the 78th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Humana's historical P/FCF ratio range?

Accepted Answer

In the available daily series, Humana (HUM) P/FCF ratio has ranged from a low of 3.3× in 2012 to a high of 381.2× in 2015. The 5-year average is 29.2× and the 5-year median is 18.6×.

Question 7

What was Humana's P/FCF ratio in 2025?

Accepted Answer

Humana (HUM) P/FCF ratio at the end of 2025 was 82.2×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month free cash flow figure available at that date.

Question 8

Why does Humana's P/FCF ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (free cash flow). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$30.8B	$375M	82.2×	+69.4×	Dec 31, 2025
2024	$30.5B	$2.39B	12.8×	-6.1×	Dec 31, 2024
2023	$56.1B	$2.98B	18.8×	+0.3×	Dec 31, 2023
2022	$64.4B	$3.47B	18.6×	-44.5×	Dec 31, 2022
2021	$59.7B	$946M	63.1×	+51.5×	Dec 31, 2021
2020	$54.2B	$4.68B	11.6×	+0.9×	Dec 31, 2020
2019	$48.5B	$4.55B	10.7×	-14.4×	Dec 31, 2019
2018	$39.1B	$1.56B	25.1×	+15.1×	Dec 31, 2018
2017	$35.1B	$3.53B	9.9×	-11.7×	Dec 31, 2017
2016	$30.5B	$1.41B	21.7×	-55.4×	Dec 31, 2016
2015	$26.6B	$345M	77.1×	+57.1×	Dec 31, 2015
2014	$21.8B	$1.09B	20.0×	+7.4×	Dec 31, 2014
2013	$16.1B	$1.28B	12.6×	+5.4×	Dec 31, 2013
2012	$10.9B	$1.51B	7.2×	-1.1×	Dec 31, 2012
2011	$14.3B	$1.73B	8.3×	+3.7×	Dec 31, 2011
2010	$9.14B	$2.02B	4.5×	-1.4×	Dec 31, 2010
2009	$7.36B	$1.24B	6.0×	-2.7×	Dec 31, 2009
2008	$6.21B	$721M	8.6×	-4.2×	Dec 31, 2008
2007	$12.6B	$985M	12.8×	+6.7×	Dec 31, 2007
2006	$9.14B	$1.49B	6.1×	-12.8×	Dec 31, 2006
2005	$8.69B	$460M	18.9×	-1.2×	Dec 31, 2005
2004	$4.7B	$234M	20.1×	+8.3×	Dec 31, 2004
2003	$3.68B	$312M	11.8×	+3.2×	Dec 31, 2003
2002	$1.79B	$209M	8.6×	—	Dec 31, 2002


Align Technology (ALGN)	17.8×
McKesson (MCK)	17.8×
Gilead Sciences (GILD)	16.9×
DexCom (DXCM)	16.9×
Pfizer (PFE)	16.7×
Quest Diagnostics (DGX)	16.3×
UnitedHealth Group (UNH)	15.9×
Labcorp Holdings (LH)	15.9×
Becton, Dickinson and (BDX)	14.0×
HCA Healthcare (HCA)	13.5×
Elevance Health (ELV)	13.4×
Incyte (INCY)	12.9×
CVS Health (CVS)	12.4×
Universal Health Services (UHS)	12.2×
Baxter International (BAX)	12.1×
Cardinal Health (CAH)	11.3×
IQVIA (IQV)	11.3×
Bristol-Myers Squibb (BMY)	10.4×
Biogen (BIIB)	10.3×
Zimmer Biomet Holdings (ZBH)	9.6×
Cigna (CI)	9.1×
Viatris (VTRS)	9.1×
DaVita (DVA)	6.9×
Teladoc Health (TDOC)	3.9×
Centene (CNC)	2.5×

P/FCF Ratio for Humana (HUM) 2002-2026

P/FCF Ratio daily chart for Humana (HUM)

Historical P/FCF Ratio for Humana (HUM) from 2002 to 2025

About P/FCF Ratio at Humana (HUM)

Humana P/FCF Ratio by Year

Humana P/FCF Ratio 2025: 82.2×

Humana P/FCF Ratio 2024: 12.8×

Humana P/FCF Ratio 2023: 18.8×

Humana P/FCF Ratio 2022: 18.6×

Humana P/FCF Ratio 2021: 63.1×

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

Humana (HUM) Key Financials